Haemophilia prophylaxis: how can we justify the costs?

Area of Science:

• Hematology
• Public Health
• Health Economics

Background:

• Severe hemophilia significantly increases mortality and reduces quality of life.
• Factor prophylaxis offers a path to a more normal life but incurs substantial costs, primarily from replacement factors.

Purpose of the Study:

• To explore societal reasons for adopting expensive factor prophylaxis for hemophilia.
• To identify factors determining the value of costly therapies for rare inherited diseases.

Main Methods:

• The study presents an argument based on five societal considerations for valuing factor prophylaxis.
• It discusses the economic implications of expensive treatments for rare diseases.

Main Results:

• Societies may value factor prophylaxis due to its focus on inherited diseases, pediatric patients, rarity, preventative nature, and the cost of ensuring product safety.

Conclusions:

• Understanding the value drivers for expensive rare disease therapies is crucial amidst rising healthcare costs.
• Further research is needed to establish the determinants of value for such treatments.